Director, Epidemiology, Medical & Payer EvidenceAstraZeneca PharmaceuticalsWilmington, Delaware, United States
OC 31.2 - Andexanet Alfa Is Associated With Lower In-Hospital Mortality Compared To 4-Factor Prothrombin Complex Concentrate In Patients With Factor Xa Inhibitor–Related Major Bleeding
Monday, June 26, 202311:00 – 11:15 ET
PB0549 - Healthcare Resource Use Among US Veterans Treated With Andexanet Alfa or 4-factor Prothrombin Complex Concentrate for Factor Xa Inhibitor-related Major Bleeding
Monday, June 26, 202318:30 – 19:30 ET
